BJMO - 2021, issue 3, march 2021
Dan Truc Nguyen , Stéphane Holbrecht , Soizic Garaud
Introduction: Immune checkpoint inhibitors (ICI) are becoming a cornerstone of therapies for many cancers. However, a new class of side effects has emerged, namely immune-related adverse events (irAEs). Many studies have suggested a potential relationship between irAEs and benefit of ICI, but little is known about the mechanisms underlying toxicity and antitumor efficacy.
Read moreBJMO - 2021, issue 3, march 2021
Anouk Goudsmit , Edouard Cubilier , Anne-Pascale Meert , Philippe Aftimos , Konstantinos Stathopoulos , Chloé Spilleboudt , Angela Loizidou
Background: Immunocompromised cancer patients are presumed to be at high risk of developing COVID-19 infection. Predisposing factors to contracting COVID-19 and to severe outcomes have been described in registries but were not compared between solid tumors and hematological malignancies.
Read moreBJMO - 2021, issue 3, march 2021
Sofia Cristovao Ferreira , Rita Saude Conde , Mariana Brandao , Gil Morgan , Evandro de Azambuja
Introduction: Pandemic Covid19 had an important impact on health care systems worldwide. Multidisciplinary tumour boards (MTB) are considered essential to provide the best care to cancer patients. The aim of this study is to evaluate the impact of Covid19 in Breast Cancer (BC) MTB worldwide.
Read moreBJMO - 2021, issue 3, march 2021
Thomas Meyskens , Iris Timmermans , Hans Wildiers , Herlinde Dumez , Daphne Hompes , Melissa Christiaens , Raf Sciot , Annouschka Laenen , Jerry Lee , Patrick Schöffski
Objective: Angiosarcoma (AS) is a rare, aggressive subtype of soft tissue sarcoma (STS). Treatment requires a multidisciplinary approach and should preferably be carried out in reference centers. We performed an in-depth analysis of patient characteristics, treatments and prognostic factors in patients (pts) with AS treated at the University Hospitals Leuven (Belgium).
Read moreBJMO - 2021, issue 3, march 2021
Catherine Percy , Géraldine Rosier , Claire Barani , Fanny Collette , Laurence Faugeras , Lionel D'Hondt
Background: Metronomic chemotherapy consists of low-dose oral chemotherapy given continuously. The antitumor activity is supposed to be due to antiangiogenic and immunomodulation effects. This retrospective analysis was done to evaluate the benefit-risk balance of this treatment in palliative setting for unselected metastatic cancer patients.
Read moreBJMO - 2021, issue 3, march 2021
Laura Tack , Tessa Lefebvre , Marlies Meersman , Hilde Vanneste , Lieselot Cool , Koen Van Eygen , Karin Stellamans , Sofie Derijcke , Philippe Vergauwe , Jos De Backer , Rebecca Chandler , Pauline Lane , Tom Boterberg , Philip R. Debruyne
Introduction: Cancer patients, survivors and caregivers often encounter severe distress, having signifi cant consequences to wellbeing, functionality and physical health. This study developed and evaluated a participatory arts programme to determine if such could help to improve the wellbeing of cancer patients and their caregivers.
Read moreBJMO - 2019, issue 2, february 2019
Guy Jerusalem
After the major advances seen in the field of HER2 positive disease, fortunately, we have now also much more treatment options available for estrogen receptor positive HER2 negative advanced breast cancer. The better understanding of the mechanisms of resistance to endocrine therapy has allowed a much more rational treatment approach. Chemotherapy is only the preferred treatment option for patients with extensive symptomatic visceral disease. Almost all of our patients receive now an endocrine therapy based approach for several lines of treatment for advanced breast cancer. As endocrine therapy alone is not highly effective most of our patients are good candidates for combined therapy approaches with targeted agents. In the frst-line setting for advanced disease, the CDK4/6 inhibitors are now the targeted agents of choice because of the excellent safety profle in addition to the rapid and pronounced antitumoral effect. Nevertheless, many questions remain unanswered today. How should we treat specific subgroups of patients such as older patients, patients with some co-morbidities, patients with visceral disease or patients presenting bone only disease? Are biomarkers available to select the most appropriate treatments? Is progression-free survival a valid endpoint of clinical trials or do we need overall survival data? What is the optimal sequence? Should we use the best drugs frst? What should be the next line therapy in this case? During my presentation I will summarize the data available today and give you my personal view concerning these questions.
Read more
Top
